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Serum high mobility group box‑1 levels
associated with cardiovascular events
after lower extremity revascularization:
a prospective study of a diabetic population
Maria Margherita Rando1†, Federico Biscetti1*†, Andrea Leonardo Cecchini2, Elisabetta Nardella1,
Maria Anna Nicolazzi1, Flavia Angelini2, Roberto Iezzi2,3, Luis H. Eraso4, Paul J. Dimuzio4, Dario Pitocco2,5,
Antonio Gasbarrini2,6, Massimo Massetti2,7 and Andrea Flex1,2

Abstract
Background: Peripheral arterial disease (PAD) is one of the most disabling cardiovascular complications of type 2
diabetes mellitus and is indeed associated with a high risk of cardiovascular and limb adverse events. High mobility
group box-1 (HMGB-1) is a nuclear protein involved in the inflammatory response that acts as a pro-inflammatory
cytokine when released into the extracellular space. HMBG-1 is associated with PAD in diabetic patients.
The aim of this study was to evaluate the association between serum HMGB-1 levels and major adverse cardiovascular
events (MACE) and major adverse limb events (MALE) after lower-extremity endovascular revascularization (LER) in a
group of diabetic patients with chronic limb-threatening ischemia (CLTI).
Methods: We conducted a prospective observational study of 201 diabetic patients with PAD and CLTI requiring LER.
Baseline serum HMGB-1 levels were determined before endovascular procedure. Data on cardiovascular and limb
outcomes were collected in a 12-month follow-up.
Results: During the follow-up period, 81 cases of MACE and 93 cases of MALE occurred. Patients who subsequently
developed MACE and MALE had higher serum HMGB-1 levels. Specifically, 7.5 ng/mL vs 4.9 ng/mL (p < 0.01) for MACE
and 7.2 ng/mL vs 4.8 ng/mL (p < 0.01) for MALE. After adjusting for traditional cardiovascular risk factors, the association between serum HMGB-1 levels and cardiovascular outcomes remained significant in multivariable analysis. In our
receiver operating characteristic (ROC) curve analysis, serum HMGB-1 levels were a good predictor of MACE incidence
(area under the curve [AUC] = 0.78) and MALE incidence (AUC = 0.75).
Conclusions: This study demonstrates that serum HMGB-1 levels are associated with the incidence of MACE and
MALE after LER in diabetic populations with PAD and CLTI.
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Background
Diabetes mellitus (DM) represents a public health problem and economic burden, with an annual cost of 327
billion dollars in the United States [1]. Peripheral arterial
disease (PAD) affects approximately 20–26% of diabetic
patients [2] and among cardiovascular complications of
diabetes it is one of the most disabling, with a significant
impact on healthcare [3]. PAD is indeed associated with
a high risk of major cardiovascular events (MACE), particularly myocardial infarction, stroke and cardiovascular
death, and major adverse limb events (MALE), including
acute limb ischemia, major vascular amputations, and
limb-threatening ischemia needing urgent revascularization [4]. In addition, patients with PAD and diabetes
have a higher risk of both MACE and MALE, compared
to those without diabetes, notwithstanding current treatment with antiplatelets, statins and antihypertensive
drugs [2].
Treatment of PAD is based on a multidisciplinary
approach, including best medical therapy, aimed at managing modifiable cardiovascular risk factors, and lower
extremity revascularization in the setting of chronic limbthreatening ischemia (CLTI) [5, 6]. Among revascularization strategies, endovascular intervention has increased
significantly in recent years, representing an effective
treatment option for improving symptoms and preventing limb loss [5, 7, 8]. After LER, however, cardiovascular and limb events occur in a considerable percentage of
patients [9–11]. Therefore, identifying biomarkers that
can predict the risk of cardiovascular complications is
necessary to develop a personalized follow-up approach.
In diabetic patients, outcomes after revascularization
may be related to multiple mechanisms, not all of which
are well defined. Diabetes accelerates the progression of
atherosclerosis in several ways, including insulin resistance and hyperinsulinemia, hyperglycemia, diabetic
dyslipidemia, advanced glycation end-product, reactive oxygen species, and inflammation [2]. Particularly,
inflammation plays a crucial role in the development
of PAD [12, 13]. In addition, C-reactive protein (CRP)
is associated with poor outcomes after LER, including
restenosis after angioplasty, risk of limb loss, cardiovascular events, and mortality [14–16]. Recently, we found
that baseline levels of osteoprotegerin (OPG), tumor
necrosis factor (TNF)-α, interleukin (IL)-6, and CRP levels were associated with adverse cardiovascular outcomes
in diabetic patients with PAD and CLTI after LER [17].

Among inflammatory biomarkers associated with the
atherosclerotic process and diabetic complications, high
mobility group box-1 (HMGB-1) plays a crucial role
in the inflammatory response responsible for vascular
injury [18, 19]. HMGB-1 is a nuclear protein involved in
inflammation, angiogenesis and tissue regeneration [20–
24] and it has been shown that it is overexpressed in diabetic patients compared to patients without diabetes [25,
26]. HMGB-1 plays a role in DNA transcription, replication and repair in the nucleus and it acts as a signal regulator in the cytoplasm. When released in the extracellular
space, it acts as a pro-inflammatory cytokine [24, 27].
HMGB-1 can be passively released after cellular injury or
cellular death, and released from immune cells (monocytes, macrophages, dendritic cells, natural killer (NK)
cells and endothelial cells) upon activation by lipopolysaccharide (LPS), TNF-α, IL-6, IL-1β, interferon (IFN)-γ
or after tissue damage [18]. Once in extracellular space,
HMGB-1 binds its receptors, receptor for advanced glycation end products (RAGE) and toll-like receptor (TLR)
s, and stimulates both the inflammatory and immune
response, involved in endothelial dysfunction and atherosclerotic process [18].
Different evidence shows a role of HMGB-1 in cardiovascular diseases development. It has been associated
with coronary artery disease (CAD) [28–31] and it represents an independent risk factor for carotid plaque vulnerability [32]. In addition, we previously observed that
levels of HMGB-1 were higher in patients with PAD and
diabetes mellitus compared to those without diabetes
mellitus [33]. Given available evidence, a role of HMBG-1
has been postulated in predicting cardiovascular outcomes after LER.
The aim of this study was to evaluate the association
between serum levels of HMGB-1 at baseline and MACE
and MALE, in diabetic patients with PAD and CLTI
requiring for LER.

Research design and methods
Study design

The prospective cohort study aimed at investigating the
association between HMGB-1 serum levels and the incidence of MACE and MALE in a population of T2DM
patients with PAD and CLTI, requiring LER. The study
has been approved by the Ethics Committee of the Fondazione Policlinico Universitario A. Gemelli IRCCS and
it adhered to the principles of the Declaration of Helsinki.
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All the subjects enrolled have given informed consent to
participate.
Study population and clinical assessment

We enrolled 212 consecutive patients with T2DM and
PAD needing LER and admitted to Internal Medicine
Cardiovascular Unit of the Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy from October
23, 2019 to June 30, 2021.
All patients over 18 years of age with a diagnosis of
T2DM present for a least one year, an Ankle/Brachial
Index (ABI) of less than 0.80, lower limb stenosis greater
than 50% documented by Ultrasound Color Doppler
(US), category 4 or 5 of PAD in accordance with the
Rutherford classification [34], presence of CLTI as previously defined [17, 35, 36], and the need for endovascular
treatment, were included in the study.
The exclusion criteria were pregnancy, acute infections at present or in the previous month, diabetic foot
ulcers with sign of infection or osteomyelitis, previous
lower-limb endovascular or surgical revascularization
within the past 3 months, diabetic peripheral neuropathy
ruled out as previously described [17], liver disease with
a functional status B or C in accord to Child–Pugh classification, congenital or acquired thrombophilia, active
autoimmune disease, active cancer, organ transplantation, life expectancy < 12 months, contraindication to
antiplatelet therapy, contraindication to endovascular
revascularization. In the presence of diabetic foot ulcer,
the Wound, Ischemia, and foot Infection (WIfI) classification system was used to classify patients, as previously
described [37, 38]. Radiological imaging was performed
to exclude osteomyelitis, if suspected. Definition of PAD
was in accordance with the Society for Vascular Surgery
and the International Society for Cardiovascular Surgery
criteria [39]. A lower-limb US evaluation was performed
in all the patients involved in the study. Moreover, people
with an ABI of 1.40 or higher, US was used to confirm the
presence of severe stenosis of the lower limb.
Demographic, clinical and laboratory tests data were
collected for all the subjects involved in the study. In
particular, data about age, sex, body mass index (BMI),
history of CAD, cerebrovascular disease (CVD), smoking habits, diabetes duration, antidiabetic medications, hypertension, hypercholesterolemia, renal failure
(defined as an estimated glomerular filtration rate
(eGRF) < 60 mL/min) were collected.
Before LER, patients were all in single antiplatelet
therapy, beginning double antiplatelet therapy (DAPT)
after revascularization procedure for 1 month. In particular, 189 patients were on aspirin and 12 patients
were on clopidogrel at baseline. After the procedure, all
patients of our cohort were on aspirin and clopidogrel.
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Furthermore, after LER, an aggressive lipid-lowering
therapy was recommended to achieve an LDL-C target
lower than 55 mg/dL, according to ESC/EAS Guidelines
for the management of dyslipidemias [40]. At baseline,
129 (62.3%) patients were taking lipid-lowering drugs,
among them 115 were on statin therapy, 10 on ezetimibe
and 4 on PCSK9 inhibitor (PCSK9i). After the enrollment, cholesterol-lowering therapy was modified in all
patients who did not meet treatment goal by changing
the type or the dose of statin or adding another drug (e.g.,
ezetimibe, PCSK9i).
Lower‑limb endovascular revascularization and follow‑up
after the procedure

Lower-limb revascularization through balloon angioplasty and/or stenting was performed as previously
described [17, 35, 36]. Revascularization was considered
successful if the residual stenosis of the treated arterial
vessel was less than 30%.
In accordance with the definitions of the Society of
Interventional Radiology, no complications related to the
endovascular procedure were recorded [41].
The incidence of MACE and MALE were assessed
in a 12-month follow-up period, with evaluation of the
patients at 1, 3, 6 and 12 months after LER procedure.
MACE was defined as composite of cardiovascular death,
stroke, or myocardial infarction [42]. MALE was defined
as a composite of acute limb ischemia, major vascular
amputations, and limb-threatening ischemia leading to
urgent revascularization [17, 42].
Blood test and biochemical assays

Blood tests were collected after an overnight fast at baseline, before LER, in all the patients enrolled in the study.
Total cholesterol, LDL cholesterol, triglycerides, glucose, creatinine, and glycated hemoglobin were assessed.
EGFR was calculated by modification of diet in renal disease (MDRD) formula. Serum was separated by centrifugation of blood samples and was stored at − 80 °C before
every analysis. Serum HMGB-1 levels were determined
by a commercially available ELISA kit (HMGB-1 ELISA
kit II; Shino-Test Corporation, Tokyo) according to its
protocol. The detection limit for HMGB-1 was 0.2 ng/
mL with an inter-assay coefficient of variation (CV) < 10%
[33]. The serum levels were measured twice for each
patient and the results were averaged.
Statistical analysis

A descriptive analysis of demographic and clinical data
was summarized as means (standard deviations) for continuous variables and counts (percentages) for categorical
variables.
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The baseline characteristics of the population were
compared using the chi-square and t-tests, when
appropriate. A log transformation was applied to the
not normally distributed variables prior to performing further analysis. Serum HMGB-1 levels were compared with Mann–Whitney, Kruskal–Wallis and Dunn’s
Multiple Comparison, when appropriate. A multivariable stepwise logistic regression analysis was performed,
adjusted for traditional cardiovascular risk factors and
HMGB-1 levels. The area under the receiver operating characteristics (ROC) curve was calculated to test
the predictive discrimination of serum HMGB-1 levels
for MACE and MALE. A second model to test the predictive discrimination HMGB-1 levels and traditional
cardiovascular risk factors (sex, age, diabetes duration,
BMI, smoking status, hypertension, previous CAD and
CVD history, treatment, total cholesterol, LDL cholesterol, triglycerides, fasting blood glucose (FBG),
HbA1c) for MACE was made, comparing the areas
under the ROC curves through the roccomp function
in STATA software.
MACE-free survival, according to HMGB-1 levels, was
evaluated using Kaplan-Mayer method and compared
using the Log-Rank test. All analyses were performed
using STATA version 14.0 for MacOS (Statistics/Data
Analysis, Stata Corporation, College Station, TX, USA)
and SPSS version 25.0 for MacOS (IBM Corporation,
Armonk, NY, USA). Statistical significance was established at p < 0.05.

Results
Characteristics of the study population

Of the 212 patients who underwent endovascular intervention, 11 (5.2%) had a poor primary outcome and were
excluded from the study follow-up.
Overall, 201 diabetic patients with PAD and CLTI were
enrolled in the study. The mean age (SD) of the subjects
involved was 74.9 (± 8.9) years and 150 (74.6%) of them
were men. The average T2DM duration was 11.4 (± 0.8)
years. Current smokers were 103 (51.2%), former smokers were 68 (33.8%) while people who had never smoked
were 31 (15.4%). Regarding PAD disease severity categories, Rutherford 4 was found in 54.2% (109 patients) of
the population and Rutherford 5 was present in 45.8%
(92 patients) one, while WIfI010 was detected in 30.3%
(61 patients), WIfI020 in 25.4% (51 patients), WIfI110 in
24.4% (49 patients) and WIfI120 in 19.9% (40 patients)
of the population. It should be noted that three patients
with proximal lesions were considered as Rutherford 5,
according to the definition of Rutherford classification
[34], and as WIfI0, according to the definition of WIfI
classification [37].
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Mean LDL-C levels were 112.2 mg/dL (± 15.4) and
mean glycated hemoglobin levels were 8.9% (± 0.7).
Mean HMGB-1 serum levels were 5.9 ng/mL (± 2.7).
The complete demographic and clinical characteristics
of the population are described in Table 1.
HMGB‑1 serum levels and incidence of MACE
during the follow‑up period after LER

During the follow-up period of 12 months, 81 patients
had a MACE after the revascularization procedure. In
particular, we observed 42 myocardial infarctions, 33
strokes and 14 deaths.
There were no differences between patients with
MACE and without MACE in terms of age (p = 0.44), sex
(p = 0.13), BMI (p = 0.22), diabetes duration (p = 0.92),
Table 1 Demographic characteristics and clinical data of the
study cohort at baseline
Number of patients

201

Men/female, n

150:51

Age, years ± SD

Diabetes duration, years ± SD

BMI, Kg/m2 ± SD

74.9 ± 8.9

11.4 ± 0.8

26.7 ± 0.6

Smoking (current), n (%)

103 (51.2)

Smoking (former), n (%)

68 (33.8)

Never smoked, n (%)

31 (15.4)

Hypertension, n (%)

146 (72.6)

Hypercholesterolemia, n (%)

109 (54.2)

CAD, n (%)

93 (46.3)

CVD, n (%)

99 (49.2)

Oral antidiabetic agents, n (%)

89 (44.3)

Insulin, n (%)

147 (73.1)

ABI, ± SD

0.6 ± 0.1

Rutherford III-5, n (%)

92 (45.8)

WIfI010, n (%)

61 (30.3)

WIfI020, n (%)

51 (25.4)

WIfI110, n (%)

49 (24.4)

WIfI120, n (%)

40 (19.9)

HbA1c, % ± SD

8.9 ± 0.7

Total cholesterol, mg/dL ± SD

218.9 ± 22.3

Rutherford II-4, n (%)

FBG, mg/dL ± SD

LDL cholesterol, mg/dL ± SD
Triglycerides, mg/dL ± SD

eGFR, mL/min/1.73m2 ± SD

HMGB-1, ng/mL ± SD

109 (54.2)

127.9 ± 9.7

112.4 ± 15.4
172.5 ± 8.5

72.6 ± 10.5

5.9 ± 2.7

Data are reported as means (standard deviation) for continuous variables and
numbers (percentages) for categorical variables
BMI, body mass index; CAD, coronary artery disease; CVD, cerebrovascular
disease; ABI, ankle brachial index; WIfI, wound, ischemia, foot infection; FBG,
fasting blood glucose; eGFR, estimated glomerular filtration rate; HMGB-1, high
mobility group box 1
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history of high blood pressure (p = 0.48) and hypercholesterolemia (p = 0.40), history of CAD (p = 0.66) and
CVD (p = 0.75), antidiabetic oral medications (p = 0.74)
and insulin (p = 0.57), total cholesterol levels (p = 0.67),
LDL-C levels (p = 0.836), ABI (p = 0.75), Rutherford category (II-4 p = 0.40, III-5 p = 0.40), glycated hemoglobin
levels (p = 0.30) and renal function (p = 0.67).
Patients with MACE had higher HMGB-1 serum levels (7.5 ± 1.9 ng/mL vs 4.9 ± 2.6 ng/mL, p < 0.01) (Fig. 1),
were active smokers (56, p < 0.01) and had higher levels
of triglycerides (174.5 ± 8. 3 mg/dL, p < 0.01), compared
to patients without MACE. Patients without MACE were
former smokers (50, p < 0.01) and never smokers (24,
p = 0.03) compared to patients with MACE. The complete characteristics of the population with and without
MACE are described in Table 2.
HMGB-1 levels were analyzed in association with
every MACE composite outcome: cardiovascular
death, myocardial infarction and stroke. In particular,
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patients who died for a cardiovascular reason had
higher levels of HMGB-1 compared to patients who
survived (8.098 ± 1.103 ng/mL vs 5.758 ± 2.647 ng/
mL, p = 0.0012). Patients with myocardial infarction
had HMGB-1 levels of 7.313 ± 1.650 ng/mL and those
without myocardial infarction 5.553 ng/mL ± 2.728
(p = 0.0001). Patients with stroke had HMGB-1 levels of
7.537 ± 2.074 ng/mL than those without stroke 5.604 ng/
mL ± 2.624 (p < 0.0001) (Fig. 1).
To predict the incidence of MACE based on serum
HMGB-1 levels, a ROC curve was elaborated. The area
under the curve (AUC) was 0.7834. (95% CI 0.7195,
0.8473) (Fig. 2).
A second model to predict the incidence of MACE
based on serum HMGB-1 levels and traditional cardiovascular risk factors (sex, age, diabetes duration, BMI,
smoking status, hypertension, previous CAD and CVD
history, treatment, total cholesterol, LDL cholesterol,
triglycerides, fasting blood glucose (FBG), HbA1c) was
made. The comparison of ROC curves between the
baseline model with only serum HMGB-1 levels and the
second model including serum HMGB-1 levels and traditional cardiovascular risk factors showed that including traditional cardiovascular risk factors improved the
prediction of MACE, with an area under the ROC curve
of 0.7063 (95% CI 0.6315, 0.7810) for the baseline model
and 0.822 (95% CI 0.7657, 0.8799) for the second model
(Fig. 3).
Based on serum HMGB-1 levels, a MACE free survival
analysis was performed using a Kaplan-Mayer curve.
Subjects with serum HMGB-1 levels higher than
6.905 ng/mL had a higher incidence of MACE compared to subjects with HMGB-1 serum levels less than
6.905 ng/mL with a sensitivity of 69.14% and a specificity
of 78.33% (p = 0.0005) (Fig. 4).
After adjustment for traditional cardiovascular risk
factors, a multivariable analysis was elaborated, showing
that ABI (p = 0.001, 95% CI 0.417, 1.549) and HMGB-1
serum levels (p < 0.000, 95% CI 0.082, 0.131) were independent risk factors for MACE in patients with PAD who
underwent LER (Table 3).
HMGB‑1 serum levels and incidence of MALE
during the follow‑up period after LER

Fig. 1 HMGB-1 levels according to MACE, mortality, coronary artery
disease (CAD), cerebrovascular artery disease (CVD). On the violin
plots, central line represents the median, upper line represents the
upper interquartile range (IQR) and the lower line represents the
lower IQR. ****p < 0.0001, **p < 0.01

During the follow-up period of 12 months, 93 patients
had a MALE after the revascularization procedure.
There were no differences between patients with
MALE and without MALE in terms of age (p = 0.19), sex
(p = 0.40), BMI (p = 0.63), diabetes duration (p = 0.77),
history of high blood pressure (p = 0.62), hypercholesterolemia (p = 0.31), history of CAD (p = 0.56), history of
CVD (p = 0.53), antidiabetic oral medications (p = 0.95)
and insulin (p = 0.06), LDL-C levels (p = 0.61), ABI

Rando et al. Cardiovascular Diabetology

(2022) 21:214

Page 6 of 14

Table 2 Demographic and clinical data of study participants without or with MACE
NO MACE (n = 120)

MACE (n = 81)

Men/female, n

85:35

65:16

0.13

Age, years ± SD

74.5 ± 9.3

75.5 ± 8.3

0.44

BMI, Kg/m2 ± SD

26.7 ± 0.6

26.8 ± 0.7

0.22

56 (69.1)

< 0.01

Smoking (former), n (%)

50 (41.7)

18 (22.2)

< 0.01

Never smoked, n (%)

24 (20.0)

7 (8.6)

0.03

Hypertension, n (%)

85 (70.8)

61 (75.3)

0.48

Hypercholesterolemia, n (%)

68 (56.7)

41 (50.6)

0.40

CAD, n (%)

54 (45.0)

39 (48.1)

0.66

CVD, n (%)

58 (48.3)

41 (50.6)

0.75

Oral antidiabetic agents, n (%)

52 (43.3)

37 (45.7)

0.74

Insulin, n (%)

86 (71.7)

61 (75.3)

0.57

ABI, ± SD

0.6 ± 0.1

0.6 ± 0.1

0.75

41 (50.6)

0.40

Rutherford III-5, n (%)

52 (43.3)

40 (49.4)

0.40

WIfI010, n (%)

32 (26.7)

29 (35.8)

0.17

WIfI020, n (%)

35 (29.2)

16 (19.8)

0.13

WIfI110, n (%)

26 (21.7)

23 (28.4)

0.27

WIfI120, n (%)

27 (22.5)

13 (16.0)

0.26

HbA1c, % ± SD

8.9 ± 0.7

8.8 ± 0.7

0.30

Total cholesterol, mg/dL ± SD

219.4 ± 21.5

218.1 ± 23.6

0.67

Diabetes duration, years ± SD

Smoking (current), n (%)

Rutherford II-4, n (%)

FBG, mg/dL ± SD

LDL cholesterol, mg/dL ± SD
Triglycerides, mg/dL ± SD

eGFR, mL/min/1.73m2 ± SD

HMGB-1, ng/mL ± SD

11.4 ± 0.9

11.4 ± 0.8

47 (39.2)

68 (56.7)

128.0 ± 10.0

127.8 ± 9.1

112.0 ± 15.4

113.0 ± 15.6

171.1 ± 8.3

72.3 ± 10.5

0.92

0.89
0.70

174.5 ± 8.3

< 0.01

7.5 ± 1.9

< 0.01

73.0 ± 10.6

4.9 ± 2.6

p value

0.67

Statistical test performed with Student’s t-test or with Chi square test, when appropriate
BMI, body mass index; CAD, coronary artery disease; CVD, cerebrovascular disease; ABI, ankle brachial index; WIfI, wound, ischemia, foot infection; FBG, fasting blood
glucose; eGFR, estimated glomerular filtration rate; HMGB-1, high mobility group box 1

(p = 0.88), Rutherford category (4 p = 0.68, 5 p = 0.68),
glycated hemoglobin levels (p = 0.10) and renal function
(p = 0.95).
Patients with MALE had higher serum HMGB-1 levels (7.2 ± 2.0 ng/mL vs 4.8 ± 2.6 ng/mL, p < 0.01) (Fig. 5),
were active smokers (56, p < 0.02) and they had higher
levels of total cholesterol (223.0 ± 20.7 mg/dL, p = 0.01),
triglycerides (173.76 ± 8.5 mg/dL, p = 0.04), compared to
patients without MALE.
The complete characteristics of the population with
and without MALE are described in Table 4.
To predict the incidence of MALE based on HMGB-1
serum levels, a ROC curve was elaborated. The area
under the curve (AUC) was 0.7532 (95% CI 0.6852,
0.8211) (Fig. 6).
After adjustment for traditional cardiovascular risk
factors, a multivariable analysis was elaborated, showing that use of insulin (p = 0.042, 95% CI 0.006, 0.297),

ABI (p = 0.015, 95% CI 0.153, 1.373), glycated hemoglobin (p = 0.002, 95% CI 0.054, 0.245), total cholesterol
(p = 0.017, 95% CI 0.001, 0.007) and serum HMGB-1 levels (p < 0.000, 95% CI 0.067, 0.120) were independent risk
factors for MALE in patients with PAD who underwent
LER (Table 5).

Discussion
In this study we have evaluated the association between
serum HMGB-1 levels and cardiovascular outcomes after
LER in a cohort of diabetic patients with PAD and CLTI,
showing an association between higher serum HMGB-1
levels and MACE and MALE during the follow-up period
after revascularization.
Despite best medical therapy and a multidisciplinary
approach, prevention of cardiovascular complications
in T2DM patients with PAD after LER already represents an unmet need. Even though similar baseline
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Fig. 4 MACE free survival according to HMGB-1 levels was evaluated
using Kaplan-Mayer method and compared using the Log-Rank test.
Serum HMGB-1 levels higher than 6.905 ng/mL was associated with
of a higher incidence of MACE compared to serum HMGB-1 levels
less than 6.905 ng/mL with a sensitivity of 69.14% and a specificity of
78.33% (p = 0.0005)

Fig. 2 Receiver operating characteristic (ROC) curve analysis to
predict incidence of MACE related to HMGB1 levels showing area
under the curve (AUC). p < 0.01

Fig. 3 Receiver operating characteristic (ROC) curves comparing
the performance of a model without (Model 1) and with (Model 2)
HMGB-1 in predicting MACE. The true-positive rate (sensitivity) is
plotted as a function of the false-positive rate (1—Specificity). p < 0.01

characteristics of the population receiving LER, some
patients develop no complications, while others have
poor outcomes even shortly after the endovascular procedure [35].

Therefore, in addition to traditional cardiovascular
risk factors, identifying predictors of adverse outcomes
after LER is necessary to prevent cardiovascular events.
Inflammation is a sine qua non for atherosclerosis
progression [43], and anti-inflammatory therapy has
been demonstrated to have an adjuvant role in the secondary prevention of cardiovascular events [44–46].
The chronic inflammatory state associated with diabetes mellitus plays a key role in macrovascular and
microvascular complications in diabetic patients [18,
47]. We previously showed in a cohort of 299 diabetic
patients with PAD that baseline OPG, TNF-α, IL-6, and
CRP levels were associated with adverse cardiovascular
outcomes after LER [17]. In addition, Bleda and colleagues found associations between CRP and fibrinogen levels with mortality and cardiovascular outcomes
at baseline and after LER [16].
HMGB-1 is a ubiquitous protein that acts as a proinflammatory cytokine in the extracellular space. It
plays a crucial role in the progression of atherosclerosis and the development of cardiovascular diseases
[18]. Once bound to its receptors (RAGE and TLRs),
HMBG-1 activates various signaling pathways, including nuclear factor-kB (NF-kB), extracellular signalregulated kinase (ERK), p38 mitogen-activated protein
kinase (p38MAPK), c-Jun N-terminal kinase (JNK),
and myeloid differentiation factor-88 (MyD88), which
promote oxidative stress and enhance the secretion
of various cytokines, including TNF-α, IL-6 and IL-1,
growth factors and adhesion molecules, contributing
to endothelial dysfunction and vascular injury [18].
HMGB-1 has been shown also to promote vascular
endothelial growth factor (VEGF) dependent angiogenesis in animal models of limb ischemia, suggesting a
role of HMGB-1 in tissue repair [48, 49].
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Table 3 Multivariable logistic regression for MACE
Coef.

St.Err.

t-value

p-value

[95% Conf Interval]
− 0.051

0.230

− 0.088

0.048

− 1.042

0.683

− 1.269

0.424

− 0.213

0.024

− 0.182

0.063

− 0.123

0.147

0.417

1.549

Men/female

0.089

0.071

1.25

0.213

Age, years

0.003

0.003

0.90

0.370

− 0.020

0.034

0.559

0.066

0.047

− 0.59

1.41

0.161

− 0.180

0.437

− 0.41

0.681

− 0.422

0.429

− 0.98

0.326

− 0.095

0.060

− 1.58

0.116

Diabetes duration
BMI
Smoking (current)
Smoking (former)
Never smoked
Hypertension
Hypercholesterolemia
CAD
CVD
Oral antidiabetic ag

− 0.357

0.434

− 0.001

0.066

0.078

0.060

− 0.059

0.062

0.190

− 0.95

0.341

0.499

− 0.131

0.129

− 0.039

0.196

− 0.136

0.107

0.287

3.43

0.001

− 0.017

0.071

− 0.24

0.811

− 0.158

0.124

WIfI010

0.180

0.092

1.95

0.053

0.069

0.094

0.73

0.466

− 0.002

0.363

WIfI020
WIfI110

0.136

0.096

1.42

0.158

WIfI120

0.000

HbA1c

− 0.062

0.045
0.003

− 1.37

0.171

0.001

0.34

0.734

− 0.002

0.001

0.152

0.002

0.002

− 1.44

0.93

0.356

Triglycerides

0.006

0.004

1.71

0.088

eGFR

0.002

0.003

0.77

0.444

HMGB-1

0.107

0.012

8.56

0.000

Constant

− 3.008

1.779

− 1.69

0.093

FBG
Total cholesterol
LDL cholesterol

Mean dependent var

0.983

1.31

− 1.213

0.864

Rutherford III-5

0.068

0.988

0.158

0.17

Rutherford II-4

0.012

− 0.01

− 0.026

0.812

ABI

0.061

0.412

0.009

− 0.24

Insulin

− 0.015

− 0.82

− 0.004

0.000

0.403

SD dependent var

R-squared

0.424

Number of obs

F-test

5.150

Prob > F

Akaike crit. (AIC)

225.220

Bayesian crit. (BIC)

0.492

− 0.117

0.256

− 0.053

0.325

− 0.151

0.027

− 0.005

0.001

− 0.001

0.013

− 0.005

0.007

− 0.003

0.007

− 0.003

0.008

0.082

0.131

− 6.520

0.503

Sig.

**

**

201.000
0.000
311.105

**p < 0.01

Higher HMGB-1 levels are associated with poor outcomes after myocardial infarction (MI) [50–52]. Specifically, Kohno and colleagues showed that patients with
ST-elevation myocardial infarction (STEMI) had higher
serum HMGB-1 levels at baseline and 12 h after the
event than patients with chronic stable angina, and this
was associated with adverse cardiovascular outcomes,
in particular pump failure, cardiac rupture and cardiac
death [50]. SØrensen and colleagues showed an association between higher HMGB-1 levels and increased
mortality after STEMI [51]. Hashimoto and colleagues
found similar results in a cohort of patients with unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI), suggesting an association

between higher HMGB-1 levels and risk of cardiovascular death [52]. We previously showed that elevated serum
HMGB-1 levels were associated with the presence and
the severity of PAD in diabetic patients, compared with
diabetic patients without PAD [33]; however, an association between HMGB-1 and poor cardiovascular and limb
outcomes after LER has not been demonstrated.
In the present study, we found that serum HMGB-1
levels in diabetic patients with CLTI were associated with
MACE after LER. In particular, patients with higher levels of HMGB-1 had a higher risk of myocardial infarction, stroke and death from cardiovascular diseases.
Smoking status and higher triglycerides levels were also
associated with MACE, in line with previous findings
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Fig. 5 HMGB-1 levels according to MALE. On the violin plots,
central line represents the median, upper line represents the upper
interquartile range (IQR) and the lower line represents the lower IQR.
****p < 0.0001
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[53]. In addition, non-smokers and former smokers were
less likely to develop a MACE. Interestingly, there were
no differences in the incidence of MACE among patients
with and without history of CAD.
The relationship between HMGB-1 levels and MACE
persisted even after adjusting for traditional cardiovascular risk factors such as age, BMI, smoking habits, hypertension, blood lipids, glycemic control and renal function,
confirming HMGB-1 as an independent risk factor. Interestingly, ABI was also associated with MACE in the multivariable analysis, supporting the results of previous
work by Mendes-Pinto and colleagues [54]. Surprisingly,
traditional cardiovascular risk factors did not appear to
play a role in cardiovascular complications after LER. A
history of CAD was not associated with MACE in multivariable analysis too. The results may be due to the small
sample size of our cohort, perhaps the intrinsic advanced
disease bias of our cohort, and the short follow-up time.
The finding, however, may also be representative of a

Table 4 Demographic and clinical data of study participants without or with MALE
NO MALE (n = 108)

MALE (n = 93)

Men/female, n

78:30

72:21

0.40

Age, years ± SD

74.1 ± 9.3

75.8 ± 8.4

0.19

BMI, Kg/m2 ± SD

26.7 ± 0.6

26.7 ± 0.7

0.63

56 (60.2)

0.02

Smoking (former), n (%)

46 (42.6)

22 (23.7)

< 0.01

Never smoked, n (%)

16 (14.8)

15 (16.1)

0.80

Hypertension, n (%)

80 (74.1)

66 (71.0)

0.62

Hypercholesterolemia, n (%)

55 (50.9)

54 (58.1)

0.31

CAD, n (%)

51 (47.2)

41 (44.1)

0.56

CVD, n (%)

51 (47.2)

48 (51.6)

0.53

Oral antidiabetic agents, n (%)

48 (44.4)

41 (44.1)

0.95

Insulin, n (%)

73 (67.6)

74 (79.6)

0.06

ABI, ± SD

0.6 ± 0.1

0.6 ± 0.1

0.88

49 (52.7)

0.68

Rutherford III-5, n (%)

48 (44.4)

44 (47.3)

0.68

WIfI010, n (%)

36 (33.3)

25 (26.9)

0.32

WIfI020, n (%)

26 (24.1)

25 (26.9)

0.64

WIfI110, n (%)

26 (24.1)

23 (24.7)

0.91

WIfI120, n (%)

20 (18.5)

20 (21.5)

0.60

HbA1c, % ± SD

8.8 ± 0.7

8.9 ± 0.7

0.10

223.0 ± 20.7

0.01

173.8 ± 8.5

0.04

Diabetes duration, years ± SD

Smoking (current), n (%)

Rutherford II-4, n (%)

11.4 ± 0.8

47 (43.5)

60 (55.6)

11.4 ± 0.8

p value

0.77

FBG, mg/dL ± SD

128.6 ± 9.8

127.1 ± 9.3

0.27

LDL cholesterol, mg/dL ± SD

111.9 ± 15.5

113.0 ± 15.4

0.61

Total cholesterol, mg/dL ± SD
Triglycerides, mg/dL ± SD

eGFR, mL/min/1.73m2 ± SD

HMGB-1, ng/mL ± SD

215.3 ± 23.1
171.4 ± 8.3

72.5 ± 10.7
4.8 ± 2.6

72.6 ± 10.4
7.2 ± 2.0

0.95
< 0.01

Statistical test performed with Student’s t-test or with Chi square test, when appropriate
BMI, body mass index; CAD, coronary artery disease; CVD, cerebrovascular disease; ABI, ankle brachial index; WIfI, wound, ischemia, foot infection; FBG, fasting blood
glucose; eGFR, estimated glomerular filtration rate; HMGB-1, high mobility group box 1
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Fig. 6 Receiver operating characteristic (ROC) curve analysis to
predict incidence of MALE related to HMGB-1 showing area under
the curve (AUC). p < 0.01

distinctive pro-inflammatory state after peripheral vascular revascularization in which HMGB-1 may have a key
role in clinical outcome prediction. Specifically, we elaborated a ROC curve that included only HMGB-1, confirming the role of HMGB-1 in predicting MACE after LER,
and a second ROC curve that included serum HMGB-1
levels and traditional cardiovascular risk factors. Comparing these ROC curves, we found that the model with
HMGB-1 and traditional cardiovascular risk factors
improved the prediction of MACE.
Interestingly, it has been demonstrated that HMGB-1
levels were associated with a number of diseased coronary vessels in patients with acute coronary disease, confirming the role of HMGB-1 in determining MACE [55].
In our study, however, we did not evaluate the extension of diseased coronary vessels given the design of the
research that aimed at evaluating HMGB-1 levels as predictor of MACE, regardless of the extension of CAD.
An additional novelty of our study is that we found a
cut-off value for HMGB-1 that could predict MACE free
survival after endovascular revascularization. HMGB-1
levels above 6.905 ng/mL predict a high risk of MACE
with a good sensitivity (69.14%) and specificity (78.33%).
Another finding of our study was that higher HMGB-1
levels were even associated with MALE after LER. Compared with patients without MALE, patients with MALE
were active smokers, were on insulin and had higher levels of total cholesterol and triglycerides. Conversely, nonsmokers were less likely to develop a MALE.
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The association between triglycerides and other cardiovascular risk factors with MALE was attenuated in
our multivariable logistic regression after adjusting for
HMGB-1, which was confirmed to be an independent
risk factor for MALE, along with the use of insulin, ABI,
glycated hemoglobin and total cholesterol levels, consistent with earlier evidence [56, 57]. Finally, the role of
HMGB-1 as a predictor of MALE was demonstrated by a
ROC curve.
Various explanations would support our results. In fact,
an important pro-atherogenic role of HMGB-1 has been
demonstrated in the literature [58–60]. HMGB-1 acts
by regulating various inflammatory factors and immune
cells; it also promotes the recruitment of vascular smooth
muscle cells (VSMCs) and foam cells in atherosclerotic
lesions [58]. VSMCs themselves enhance HMGB-1 secretion in an autocrine loop, which may lead to neointimal
hyperplasia responsible of restenosis after angioplasty
[58]. Furthermore, Wang and colleagues demonstrated
that LPS/ATP activation of NLRP3 inflammasome
stimulates HMGB-1 release leading to cholesterol accumulation in VSMCs and foam cells formation during atherosclerosis, through the downregulation of LXRa and
ABCA1 expression [60]. HMGB-1 is even responsible
for atherosclerotic plaque vulnerability, possibly through
VSMCs secretion of matrix metalloproteinase (MMP),
enzymes responsible for matrix degradation [32, 61].
Interestingly, high expression of HMGB-1 was found in
platelet-rich coronary thrombus from MI patients [62],
suggesting that activated platelet-derived HMGB-1 may
represent a link between atherothrombosis and inflammation [63]. In fact, activated platelets have been found
to be the major source of HMGB-1 in thrombi, and activated platelet-derived HMGB-1 has been shown to play a
key role in small vessels thrombosis, by promoting platelet aggregation, platelet granule secretion, and immune
cells recruitment [63]. Moreover, a study by Lv and colleagues showed that HMGB-1 is able to induce tissue
factor expression in endothelial cells and macrophages
through TLR4, TLR2, RAGE receptors and through
transcriptional factors, such as NF-kB and Egr-1, favoring atherothrombosis [64]. A similar result was found by
Sugimoto and colleagues that demonstrated an enhanced
tissue factor expression by HMGB-1 in human aortic
endothelial cells [65].
The evidence discussed supports our findings and
indeed HMGB-1 may be an essential mediator of acute
cardiovascular outcome after LER and in acute limb
adverse events after revascularization.
This study, however, has several limitations. First, this is
a single-center study based only on the Italian population
and the cohort analyzed was relatively small. Therefore, the
results cannot be applied to other ethnic groups and must be
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Table 5 Multivariable logistic regression for MALE
Coef.
Men/female
Age, years
Diabetes duration
BMI
Smoking (current)
Smoking (former)
Never smoked
Hypertension
Hypercholesterolemia
CAD
CVD
Oral antidiabetic ag
Insulin
ABI
Rutherford II-4
Rutherford III-5

− 0.017
0.005

− 0.016
0.027

− 0.288

− 0.458

− 0.191

− 0.072

St.Err.

t-value

0.077

− 0.22

0.004
0.037
0.050
0.471
0.467
0.462
0.071

0.048

0.065

0.029

0.064

1.34

− 0.42
0.54

− 0.61

− 0.98

− 0.41

− 1.01

p-value
0.829
0.181
0.676
0.590
0.542
0.328
0.680
0.315

0.75

0.456

0.45

0.653

0.019

0.067

0.28

0.782

− 0.037

0.066

− 0.55

0.580
0.042

0.006

0.297

*

0.153

1.373

*

− 0.029

0.077

− 0.38

0.706

− 0.181

0.123

0.000

0.26

0.795
0.232

WIfI110

0.070

0.103

0.67

0.501

WIfI120

0.000

− 0.171

− 0.079

− 0.134

0.223
0.323
0.274

0.149

0.049

3.08

0.002

0.054

0.245

− 0.001

0.003

− 0.30

0.765

− 0.008

0.006

0.004

0.002

0.000

0.003

Triglycerides

0.005

0.004

eGFR

0.000

0.003

2.42

0.017

− 0.07

0.944

1.31

0.192

0.11

0.914

HMGB-1

0.093

0.013

6.95

0.000

Constant

− 4.110

1.918

− 2.14

0.033

F-test

0.150
0.094

0.015

1.20

Akaike crit. (AIC)

− 0.113

− 0.167

0.175
0.156

2.05

0.100

Mean dependent var

− 0.079

− 0.098

0.721
0.069

2.47

0.102

R-squared

− 1.103

− 0.212

0.642
0.464

0.074

0.026

Total cholesterol

− 1.217

− 1.381

0.058
0.127

0.309

0.122

LDL cholesterol

− 0.089

− 0.072

0.135
0.012

0.151

WIfI010

HbA1c

− 0.168

− 0.002

Sig.

0.763

WIfI020

FBG

[95% Conf Interval]

0.463

SD dependent var

0.352

Number of obs

3.807
255.362

Prob > F
Bayesian crit. (BIC)

0.500

0.001

0.007

− 0.005

0.005

− 0.003

− 0.006

**
*

0.012
0.006

0.067

0.120

− 7.894

− 0.325

**
*

201.000
0.000
341.248

**p < 0.01
*p < 0.05

validated in larger patient groups. The small sample size may
be the reason why the multivariable analysis failed to capture
the effects of traditional risk factors on MACE and MALE,
along with the short follow-up time of observation.
Furthermore, we did not assess levels of other
cytokines, so we could not conclude whether the association between HMGB-1 and poor adverse events after
LER remained significant after adjusting for other inflammatory parameters.
Another limitation of the study is that we did not evaluate changes in HMGB-1 levels during follow-up after LER
and their impact on cardiovascular adverse events. Our

goal, however, was to identify a biomarker that at baseline could predict poor outcome after revascularization.

Conclusion
To the best of our knowledge, this study demonstrates a
novel association between baseline serum HMGB-1 levels with MACE and MALE in diabetic PAD patients with
CLTI after LER. This association furthers the understanding of the key role endothelial mediated inflammation
plays in post-revascularization cardiovascular complications and may highlight a distinctive mechanistic
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pathway that can facilitate the development of novel personalized strategies to prevent cardiovascular events.
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